Photo Gallery

Login

Search

News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from  7.454 to 7.632  due to high quality Publication at International Level

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • WJPPS MAY ISSUE PUBLISHED
  • MAY 2020 Issue has been successfully launched on 1 May 2020.

Abstract

STATIN THERAPY: A PROSPECTIVE EVALUTION IN SAFETY PROFILE

A. Farsena*, Dr. C. I. Sajeeth and Dr. Anoop Gopinath

ABSTRACT

Aim and Objective: To report the adverse events (AEs) associated with statin use, their causality assessment by using Naranjo scale thereby evaluating the safety profile. Materials and Method: The study involving 212 patients were conducted as a hospital based prospective study over a period of 5 months. A total of 212 cases were included in this study. Outpatients of both gender and of age 30 years and above with statin therapy, Patients prescribed with statin for more than 45days. The details on demographic characteristics and patients were enquired about any adverse events linked to the statin therapy using questionnaire. Causality assessment for adverse events was done by using Naranjo causality assessment scale. Results: Adverse events are reported as 79% in the study population. 44% of the AEs are reported in the age group of 60-69. Majority of adverse events were reported in Atorvastatin 57%. 33% of the adverse event was Myalgia followed by Constipation(17%), Fatigue(15%), Hyperglycemia(12%), Flatulence(10%), Dizziness(6%), Weight Loss (5%), and Cognitive Problems (1%). The causality assessment of adverse events by Naranjo scale revealed that 79% of ADR was possible, 19% was probable and 1% is definite (Table 8, Fig 6). Conclusion: Myalgia and Hyperglycemia is the reported AEs which required laboratory monitoring. Rosuvastatin reported high adverse events; hence prescribing Atorvastatin can be initiated over Rosuvastatin in possible conditions. Observation of safety profile can be

Keywords: followed in clinical practice and special attention can be given in the patients belonging to definite and probable.


[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More